Soricimed reports first cohort completion in Phase 1b trial of SOR-C13


Closely-held Soricimed Biopharma reported that the MD Anderson Cancer Center completed the first cohort in its investigator-initiated trial of Soricimed’s SOR-C13.

The trial, launched in September 2019, is building on the results observed in Soricimed’s Phase 1 clinical trial in patients with late-stage solid tumor cancer.

The Phase 1b trial aims to refine SOR-C13’s dosing and further explore its safety, and includes an expansion cohort to more closely assess SOR-C13’s early efficacy. 

First cohort results from the dose escalation phase of the trial, which focused on late-stage pancreatic cancer patients, showed that SOR-C13 is safe and well-tolerated.  Patients in the second cohort will receive a higher dose level of SOR-C13.

“The results from the first cohort continue to support the safety profile of SOR-C13”, Dr. Siqing Fu, the study’s principal investigator, said in a statement.

“We are encouraged by the speed of patient recruitment and are excited to start the next cohort at higher dose levels,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.